These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevention and treatment of age-related macular degeneration: an update for pharmacists. Marshall LL; Roach JM Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192 [TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Age-Related Eye Disease Study Research Group Arch Ophthalmol; 2001 Oct; 119(10):1417-36. PubMed ID: 11594942 [TBL] [Abstract][Full Text] [Related]
5. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737 [TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Melamud A; Stinnett S; Fekrat S Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144 [TBL] [Abstract][Full Text] [Related]
7. [Metabolic therapy for early treatment of age-related macular degeneration]. Fehér J; Kovács B; Kovács I; Schvöller M; Corrado Balacco G Orv Hetil; 2007 Dec; 148(48):2259-68. PubMed ID: 18039616 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
14. Dietary intake of antioxidants and risk of age-related macular degeneration. van Leeuwen R; Boekhoorn S; Vingerling JR; Witteman JC; Klaver CC; Hofman A; de Jong PT JAMA; 2005 Dec; 294(24):3101-7. PubMed ID: 16380590 [TBL] [Abstract][Full Text] [Related]
15. Current therapeutic approaches in neovascular age-related macular degeneration. Nguyen DH; Luo J; Zhang K; Zhang M Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948 [TBL] [Abstract][Full Text] [Related]
16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
17. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N; Damico L; Shams N; Lowman H; Kim R Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. El-Mollayess GM; Noureddine BN; Bashshur ZF Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219 [TBL] [Abstract][Full Text] [Related]
19. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Silva R; Cachulo ML; Fonseca P; Bernardes R; Nunes S; Vilhena N; Faria de Abreu JR Ophthalmologica; 2011; 226(3):110-8. PubMed ID: 21822000 [TBL] [Abstract][Full Text] [Related]